Quantcast

Latest pharmaceutical industry Stories

2014-10-27 08:30:53

Ferrer Purchases $8 Million of Alexza Common Stock through New Investment and Elimination of Potential Milestone Payments MOUNTAIN VIEW, Calif. and BARCELONA, Spain, Oct. 27, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) announced today that they have amended their agreement for ADASUVE(®) (Staccato(®) loxapine). Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America and the...

2014-10-27 08:27:57

Addition of Respected Clinical Trials Company Expands MPI Research Capabilities to Include Human Phase I Testing MATTAWAN, Mich., Oct. 27, 2014 /PRNewswire/ -- MPI Research today announced it has acquired the assets of Kalamazoo, Mich.-based Jasper Clinical Research & Development, Inc. Jasper is a respected clinical research organization that provides early-stage human clinical testing of promising new drugs, and is well known to pharmaceutical and biotechnology companies...

2014-10-25 23:00:42

He will lead all research and development for the firm’s algae proteins used in human pharmaceuticals and specialty animal feed products. San Diego, CA (PRWEB) October 25, 2014 Triton Algae Innovations, a pioneer in synthetic biology, today announced Dr. Xun Wang has joined the firm as President and Director of all Research & Development. Triton has developed a patented synthetic biology platform for the production of high value algae-based proteins. According to Dr. Wang, the...

2014-10-24 08:26:28

Company Name Officially Changes from Access Pharmaceuticals, Inc. to PlasmaTech Biopharmaceuticals, Inc. DALLAS and NEW YORK, Oct. 24, 2014 /PRNewswire/ -- PlasmaTech Biopharmaceuticals, Inc. (OTCQB: ACCPD), formerly Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company advancing patient care in critical areas, announced it has implemented a 1-for-50 reverse split of its common stock effective at the opening of trading on Friday, October 24, 2014. PlasmaTech's common stock...

2014-10-24 08:26:25

Company CEO to present on October 28, 2014 JERUSALEM, October 24, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company's CEO, Nadav Kidron will present at FireRock Capital's Micro-Cap Conference. Presentation Details: FireRock Capital's Annual Micro-Cap Conference Date:...

2014-10-23 08:36:17

Cite Barriers to Genetic Testing, Access to New Therapies as Thwarting Progress WASHINGTON, Oct. 23, 2014 /PRNewswire-USNewswire/ -- At a time when cancer drug development is at a critical juncture, accelerating the delivery of promising new treatments will depend on one critical requirement: ensuring that patients, individually and collectively, are actively involved in the cancer research and drug development process from beginning to end. This was the consensus of leading...

2014-10-23 08:36:04

CHENGDU, China, Oct. 23, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates that its Qionglai Facility (QLF) Good Manufacturing Practice (GMP) certification by the China Food & Drug Administration's (CFDA) is on schedule. The Company forecasts that the QLF may receive...

2014-10-23 08:35:32

DUBLIN, Oct. 23, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals, Inc. and Amneal Pharmaceuticals' Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis' Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol...

2014-10-23 04:21:52

BARCELONA, Spain, October 23, 2014 /PRNewswire/ -- Clients benefit from complete access, visibility, and control throughout the clinical trial inVentiv Health Clinical, a leading global supplier of drug development services, will replace its electronic trial master file (eTMF) content management system with Veeva Vault eTMF. Cloud-based, multitenant Vault eTMF delivers secure, instant access to inspection-ready documentation...

2014-10-22 23:08:40

Global Rupture Disc Market 2014-2018 is the new research report available to Sandlerresearch.org store at http://www.sandlerresearch.org/global-rupture-disc-market-2014-2018.html. Dallas, Texas (PRWEB) October 22, 2014 One of the major emerging trends in the market is the development of the advanced burst disc which has 99.99 percent reliability and has a life span of over two years. The Global Rupture Disc market is presently witnessing the development of advanced burst discs, which are...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related